Results 91 to 100 of about 6,478 (160)

Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches. [PDF]

Molecules
Nodola P, Molefe PSS, Tseki PF, Gumede NJ.   +3 more
europepmc   +1 more source

Pharmacokinetics of Nirmatrelvir/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participants. [PDF]

Clin Drug Investig
Li N, Yu J, Wu J, Zhang J, Ma Y, Zhang C, Han X, Gerhart J, Cong S.   +8 more
europepmc   +1 more source

Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. [PDF]

Pulm Ther
Alraddadi BM, Almaghrabi RS, Bosaeed M, Kamal M, Hassanien A, Hammam H, Zanotti G, Ikizler BK, d'Hellencourt FL, Spinardi JR, Wang L, Kyaw MH.   +11 more
europepmc   +1 more source

Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals. [PDF]

ChemMedChem
Alugubelli YR, Vulupala VR, Yang KS, Khatua K, Blankenship LR, Kumar S, Coleman D, Guo X, Geng ZZ, Cho CD, Sankaran B, Neuman BW, Xu S, Liu WR.   +13 more
europepmc   +1 more source

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir. [PDF]

J Virol
Chen L, Su H, Shang W, Nie T, Kuang W, Wang C, Shao Q, Zhang L, Liu W, Xu Y, Zhang Y.   +10 more
europepmc   +1 more source

Is it "Time to Eliminate" Time to Elimination of Symptoms as a Primary Trial End Point for Drugs Targeting Respiratory Viruses? [PDF]

J Infect Dis
Schiffer JT, Esmaeili S, Owens K, Boeckh M, Waghmare A.   +4 more
europepmc   +1 more source

Identification and characterization of a SARS-CoV-2 M^pro G23 deletion ensitrelvir-resistant mutant. [PDF]

mBio
Ma Y, Ye C, Rahisuddin R, Mahmoud SH, Cupic A, Khalil AM, Castro E, Jackson N, Bayoumi M, Arya S, Gupta YK, García-Sastre A, Plemper RK, Martinez-Sobrido L.   +13 more
europepmc   +1 more source

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source

Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study. [PDF]

BMC Prim Care
Kasher C, Distelman-Menachem T, Bareket-Samish A, Shapiro Ben David S.   +3 more
europepmc   +1 more source